← All trials
NCT05160363
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- Dec 16, 2021
- Last posted
- Dec 16, 2021
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medicines for Malaria VentureLead sponsor
- Richmond PharmacologyOverall official - principal investigator
- Richmond PharmacologyCollaborator
- Medicines for Malaria VentureStudy director
- PharmaKinetics Laboratories Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.